Doris Duke Charitable Foundation   Report issue

Foundation Phase 1 Phase 2 Phase 3 Phase 4
Founded: New York NY United States (1996)

Organization Overview

First Clinical Trial
2003
NCT01556906
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Doris Duke Charitable Foundation

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Carcinoma, Renal Cell (Phase 1)

Carotid Stenosis (Phase 2)

Colorectal Neoplasms (Phase 2)

Hypercholesterolemia (Phase 2)

Hyperlipoproteinemia Type II (Phase 2)

Inflammation (Phase 1)

Kidney Neoplasms (Phase 1)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Malaria (Phase 3)

Myelodysplastic Syndromes (Phase 2)

Pneumonia (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 35